KaloCyte’s experimental synthetic red blood cell product ErythroMer could provide a solution to the high need for treating trauma in both military and civilian settings. The company was tapped to participate in a federally-funded program to develop a synthetic blood substitute.
Image: https://biobuzz.io/
{iframe}https://biobuzz.io/baltimores-kalocyte-partners-on-46m-darpa-program-to-develop-synthetic-blood-product/{/iframe}